In this review:
This publication summarises and discusses use of the 4CMenB vaccine (BEXSERO®) against group B meningococcal disease in two recent studies published in the New England Journal of Medicine. The first study evaluated the effect of 4CMenB on the incidence of invasive meningococcal group B disease in infants and children, 3 years after inclusion in the national vaccination programme in England. The effectiveness of 4CMenB was also assessed. The second study evaluated the effect of 4CMenB on carriage of meningococcal group B disease in adolescents, in a South Australian randomised controlled trial.
Download PDF